Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Desease

Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels

Abstract

Tacrolimus (Prograf®, FK506, Fujisawa Healthcare) is a widely used immunosuppressive agent that is used both for the prevention and treatment of solid organ transplant rejection as well as for the prevention and treatment of graft-versus-host disease after allogeneic blood and marrow transplant. Oral preparations of tacrolimus are commercially available in 0.5, 1 and 5 mg gelatin capsules. Previously, only a 0.5 mg/ml oral suspension has been demonstrated to be stable for use in pediatric patients. On our bone marrow transplant service, we found that using this concentration of tacrolimus led to confusion, with patients and their caregivers confusing milligrams and milliliters, thus increasing errors with this formulation. We postulated that a 1 mg/ml oral formulation of tacrolimus would decrease the potential for medication errors. Our findings support new stability information of approximately 4 months for an extemporaneous oral suspension of tacrolimus at a concentration of 1 mg/ml.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, Aoki H et al. FK506: historical perspectives. Transplant Proc 1991; 23: 2713–2717.

    CAS  PubMed  Google Scholar 

  2. Prograf package insert. Fujisawa: Deerfield, IL, April 1994.

  3. Jacobson PA, Johnson CE, West NJ, Foster JA . Stability of tacrolimus in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 1997; 54: 178–180.

    CAS  PubMed  Google Scholar 

  4. Taormina D, Abdallah HY, Venkataramanan R, Logue L, Burckart GJ, Ptachcinski RJ et al. Stability and sorption of FK506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride and polyolefin containers. Am J Hosp Pharm 1992; 49: 119–122.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P L McCarthy Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elefante, A., Muindi, J., West, K. et al. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplant 37, 781–784 (2006). https://doi.org/10.1038/sj.bmt.1705320

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705320

Keywords

This article is cited by

Search

Quick links